Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rakesh Doshetty

Interventional Cardiology Chicago, IL Medical Doctor

NPI 1174906515 CMS profile 2781470

7447 W Talcott Ave, Ste 304, Chicago, IL 60631

Open in the dashboard

General payments

$10,178

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rakesh Doshetty of Chicago, IL is reported in the CMS Open Payments database as having received $10,178 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,385 52
2024 General $2,155 33
2023 General $440 12
2022 General $697 20
2021 General $635 19
2020 General $346 18
2019 General $521 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rakesh Doshetty
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Rakesh Doshetty were reported at $5,385. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Rakesh Doshetty Interventional Cardiology median Middle half National median
2019 $521 $1,097 $329–$3,048 $163
2020 $346 $473 $161–$1,480 $114
2021 $635 $677 $233–$1,827 $132
2022 $697 $978 $333–$2,724 $149
2023 $440 $1,136 $382–$2,986 $160
2024 $2,155 $1,181 $395–$3,326 $164
2025 $5,385 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,384 9 payments
  2. Abbott Laboratories $2,345 18 payments
  3. Abiomed $1,733 15 payments
  4. Shockwave Medical, Inc $634 15 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $520 16 payments
  6. Janssen Pharmaceuticals, Inc $358 11 payments
  7. AstraZeneca Pharmaceuticals LP $312 16 payments
  8. Pfizer Inc. $230 7 payments
  9. Novartis Pharmaceuticals Corporation $230 11 payments
  10. Boston Scientific Corporation $212 2 payments
  11. Other $1,219 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,395 149 payments
  2. Travel and Lodging $3,291 11 payments
  3. Education $492 8 payments
Products named General payments · program years 2019–2025
  1. Indigo System $2,384 9 payments
  2. PERCLOSE PROGLIDE $2,019 14 payments
  3. Impella $1,451 11 payments
  4. LifeVest $520 16 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $458 14 payments
  6. XARELTO $358 11 payments
  7. VERQUVO $198 11 payments
  8. BRILINTA $182 9 payments
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $177 1 payment
  10. LEQVIO $159 7 payments
  11. Other $2,052 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

70

Median for Hospitalist: 109

Drug cost

$562

Median for Hospitalist: $6,399

Branded share of claims

0%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metoprolol Succinate Generic 24 $313
Atorvastatin Calcium Generic 21 $99
Lisinopril Generic 13 $94
Carvedilol Generic 12 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $68
$68 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $32
$32 — —
Repatha
  • Amgen Inc. $18
$18 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $16
$16 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record